Mirae Asset Global Investments Co., Ltd. Atai Life Sciences N.V. Transaction History

Mirae Asset Global Investments Co., Ltd.

  • $20 Billion
  • Q2 2024

A detailed history of Mirae Asset Global Investments Co., Ltd. transactions in Atai Life Sciences N.V. stock. As of the latest transaction made, Mirae Asset Global Investments Co., Ltd. holds 4,998 shares of ATAI stock, worth $6,497. This represents 0.0% of its overall portfolio holdings.

Number of Shares
4,998
Holding current value
$6,497
% of portfolio
0.0%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Jul 30, 2024
BUY
$1.27 - $2.6 $6,347 - $12,994
4,998 New
4,998 $6,000
Q4 2023

Jan 24, 2024
SELL
$1.04 - $1.55 $8,354 - $12,451
-8,033 Reduced 1.27%
623,677 $879,000
Q3 2023

Oct 26, 2023
BUY
$1.27 - $2.28 $110,996 - $199,269
87,399 Added 16.06%
631,710 $814,000
Q2 2023

Aug 10, 2023
SELL
$1.44 - $2.19 $92,481 - $140,648
-64,223 Reduced 10.55%
544,311 $936,000
Q1 2023

May 04, 2023
BUY
$1.17 - $2.7 $194,121 - $447,973
165,916 Added 37.49%
608,534 $1.1 Million
Q4 2022

Feb 09, 2023
SELL
$2.38 - $3.55 $16,072 - $23,973
-6,753 Reduced 1.5%
442,618 $1.18 Million
Q3 2022

Nov 10, 2022
SELL
$3.14 - $4.87 $28,181 - $43,708
-8,975 Reduced 1.96%
449,371 $1.49 Million
Q2 2022

Jul 26, 2022
BUY
$3.03 - $5.32 $122,739 - $215,502
40,508 Added 9.69%
458,346 $1.67 Million
Q1 2022

May 10, 2022
BUY
$4.66 - $7.66 $464,518 - $763,564
99,682 Added 31.33%
417,838 $2.13 Million
Q4 2021

Feb 08, 2022
BUY
$6.82 - $17.8 $171,141 - $446,673
25,094 Added 8.56%
318,156 $2.43 Million
Q3 2021

Nov 15, 2021
BUY
$13.62 - $19.48 $3.99 Million - $5.71 Million
293,062 New
293,062 $4.33 Million

Others Institutions Holding ATAI

# of Institutions
99
Shares Held
12.7M
Call Options Held
9.2K
Put Options Held
118K
View Full List

About ATAI Life Sciences N.V.

ATAI Quotes by TradingView
  • Ticker ATAI
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 165,875,008
  • Market Cap $216M
  • Description
  • Atai Life Sciences N.V., through its subsidiary, ATAI Life Sciences AG, operates as a clinical-stage biopharmaceutical company. It engages in developing various therapeutic candidates that focuses on various mental health disorders. The company's therapeutic candidates include PCN-101, a subcutaneous formulation of R-ketamine for the treatment o...
More about ATAI
Track This Portfolio

Track Mirae Asset Global Investments Co., Ltd. Portfolio

Follow Mirae Asset Global Investments Co., Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Mirae Asset Global Investments Co., Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Mirae Asset Global Investments Co., Ltd. with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email